// App-Quantinova.ai

202 : A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results

Researchers

Presenter

  • Sundar Jagannath

Principal Investigators

  • Philippe Moreau

  • Wei Deng

  • Glenn Kroog

  • Anil K Singhal

  • Sagar Lonial

  • Andrzej Jakubowiak

  • Marc S Raab

  • Thierry Facon

  • Ravi Vij

  • Darrell J. White

  • Donna Reece

  • Lotfi Benboubker

  • Jeffrey A. Zonder

Medical Centers

  • Heidelberg University Medical Center and German Cancer Research Center, Heidelberg, Germany

  • Mount Sinai Medical Center, New York, NY

  • Service Hematologie et Therapies Cellulaires, Centre Regional de Cancerologie Henry Kaplan CHRU de Tours, Hopital Bretonneau, Tours, France

  • Service des Maladies du Sang, Hopital Claude Huriez, Lille, France

  • Division of Hematology, Queen Elizabeth II Health Sciences Ctr., Halifax, NS, Canada

  • Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada

  • Hematology Department, University Hospital, Nancy, France

Locations

  • United States

  • Germany

  • France

  • Canada

Companies

  • Bristol-Myers Squibb

  • Abbott

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Multiple Myeloma

  • Alpha-thalassemia myelodysplasia syndrome

  • Thrombocytopenia

  • Hyperglycemia

  • Neutropenia

  • Lymphocytopenia

  • Anemia

  • Sepsis

Biomarkers

  • N/A

Drug/Treatment

  • Methylprednisolone

  • Diphenhydramine

  • Derma-Pax lotion

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Acetaminophen

  • Lenalidomide

  • Thalidomide

  • Ranitidine

  • Bortezomib

  • Elotuzumab

Outcome

  • N/A

Study Design

  • randomized

Phase

  • II

Study Id's

  • NCT01335399

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved